[Circadian urinary excretion of catecholamine, plasma atrial natriuretic peptide, endothelin and neuropeptide Y in obese patients with hypertension]

What Was Tested

The paper reports a study of ANP (Atrial Natriuretic Peptide) and Neuropeptide Y, published as a controlled clinical trial.

The present study tested the role of atrial natriuretic peptide (ANP), endothelin-1,2 (ET-1,2) and neuropeptide Y (NPY) in pathogenesis of obesity hypertension.

The plasma concentrations of ANP, ET-1,2 and NPY were determined in the peripheral venous blood by radioimmunoassay in 27 obese hypertensive patients (group I), in 24 obese normotensive patients (group II), and in 35 normal subjects (group III).

Who Took Part

The study group was 27 patients.

PubMed indexes the participants as teenagers, adults, middle-aged adults and older adults, men only.

What Was Measured

The present study tested the role of atrial natriuretic peptide (ANP), endothelin-1,2 (ET-1,2) and neuropeptide Y (NPY) in pathogenesis of obesity hypertension.

The subject headings attached to it are Atrial Natriuretic Factor, Catecholamines, Endothelin-1, Endothelin-2, Hypertension, Neuropeptide Y and Obesity.

What This Means in Plain Language

This is a controlled clinical trial of ANP (Atrial Natriuretic Peptide) and Neuropeptide Y in 27 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1997 (Polskie Archiwum Medycyny Wewnetrznej), a journal based in Poland.

More context: the ANP (Atrial Natriuretic Peptide) compound page and the Neuropeptide Y compound page, all human trials.